GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shenzhen Chipscreen Biosciences Co 688321.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

21.00

-0.57%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥909.5m

FY2016FY2025

Net income

CN¥51.1m

FY2016FY2025

Free cash flow

−CN¥81.6m

FY2016FY2025

Shareholders' equity

CN¥1.66bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥909.5mCN¥657.9mCN¥523.7mCN¥529.9mCN¥430.4mCN¥269.5mCN¥173.8mCN¥147.7mCN¥110.5mCN¥85.4m
Gross profitCN¥909.5mCN¥570.5mCN¥466.7mCN¥499.9mCN¥408.9mCN¥256.0mCN¥166.5mCN¥142.2mCN¥105.2mCN¥83.2m
Research and developmentCN¥221.6mCN¥214.5mCN¥270.4mCN¥163.7mCN¥130.0mCN¥92.3mCN¥51.4mCN¥43.2mCN¥37.6mCN¥32.4m
Operating incomeCN¥50.9m−CN¥80.5mCN¥97.1mCN¥16.0mCN¥22.3mCN¥37.0mCN¥21.7mCN¥32.6mCN¥24.5mCN¥2.0m
Net incomeCN¥51.1m−CN¥114.6mCN¥88.8mCN¥17.5mCN¥22.0mCN¥31.0mCN¥19.4mCN¥31.2mCN¥24.1mCN¥5.2m
Diluted earnings per share0.13-0.280.220.040.050.080.070.090.060.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥3.65bnCN¥3.25bnCN¥3.20bnCN¥2.90bnCN¥1.89bnCN¥1.73bnCN¥1.69bnCN¥716.3mCN¥656.0mCN¥403.1m
Cash and short-term investmentsCN¥636.4mCN¥469.4mCN¥850.1mCN¥799.7mCN¥382.2mCN¥580.6mCN¥380.2mCN¥131.3mCN¥102.5mCN¥108.6m
Total liabilities−CN¥1.66bnCN¥1.67bnCN¥1.49bnCN¥1.32bnCN¥476.8mCN¥232.4mCN¥245.1mCN¥239.4mCN¥205.5mCN¥189.7m
DebtCN¥1.04bnCN¥1.20bnCN¥1.04bnCN¥810.1mCN¥151.5mCN¥60.0mCN¥104.8mCN¥87.5mCN¥75.0mCN¥30.0m
Shareholders' equityCN¥1.66bnCN¥1.58bnCN¥1.59bnCN¥1.52bnCN¥1.42bnCN¥1.49bnCN¥1.45bnCN¥476.9mCN¥450.6mCN¥213.4m
Shares outstanding408m408m409m405m408m410m275m359m408m408m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥97.0mCN¥76.1m−CN¥143.2mCN¥43.3mCN¥124.8mCN¥93.6m−CN¥24.6mCN¥22.8mCN¥2.7mCN¥59.8m
Capital spending−CN¥178.6m−CN¥268.5m−CN¥229.0m−CN¥400.2m−CN¥288.5m−CN¥336.3m−CN¥133.0m−CN¥140.7m−CN¥132.8m−CN¥65.8m
Free cash flow−CN¥81.6m−CN¥192.4m−CN¥372.2m−CN¥356.9m−CN¥163.7m−CN¥242.6m−CN¥157.6m−CN¥118.0m−CN¥130.1m−CN¥6.0m
Dividends paid−CN¥31.7m−CN¥27.6m−CN¥18.7m−CN¥12.2m−CN¥4.2m−CN¥3.3m−CN¥1.5m−CN¥549,890−CN¥2.3m−CN¥3.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥286.2mCN¥257.0mCN¥235.4mCN¥267.6mCN¥244.3mCN¥162.3mCN¥176.8mCN¥179.0m
Gross profitCN¥248.4mCN¥220.5mCN¥321.1mCN¥235.6mCN¥213.9mCN¥139.0mCN¥149.1mCN¥155.7m
Operating incomeCN¥61.0mCN¥42.1m−CN¥19.5mCN¥42.3mCN¥46.7m−CN¥18.6m−CN¥49.5m−CN¥2.4m
Net incomeCN¥43.1mCN¥28.3m−CN¥19.7mCN¥41.2mCN¥48.7m−CN¥19.2m−CN¥63.5m−CN¥10.1m
Diluted earnings per share0.110.07-0.050.100.12-0.05-0.16-0.02
Cash from operations———CN¥2.0mCN¥42.0mCN¥19.0m—CN¥61.0m
Capital spending−CN¥70.0m−CN¥100.0m−CN¥63.0m−CN¥61.0m−CN¥35.0m−CN¥17.0m−CN¥57.0m−CN¥122.0m
Free cash flow———−CN¥59.0mCN¥7.0mCN¥2.0m—−CN¥61.0m
Total assetsCN¥4.60bnCN¥4.58bnCN¥3.65bnCN¥3.63bnCN¥3.43bnCN¥3.31bnCN¥3.25bnCN¥3.34bn
Cash and short-term investments——CN¥636.4mCN¥636.4mCN¥567.2mCN¥502.4mCN¥469.4mCN¥481.8m
DebtCN¥1.09bnCN¥1.05bnCN¥1.04bnCN¥426.1mCN¥1.16bnCN¥1.27bnCN¥1.19bnCN¥1.18bn
Shareholders' equityCN¥2.55bnCN¥2.58bnCN¥1.66bnCN¥1.66bnCN¥1.61bnCN¥1.56bnCN¥1.58bnCN¥1.64bn

Financial ratios

Data as of 2 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin100.0%86.7%89.1%94.3%95.0%95.0%
Operating margin5.6%-12.2%18.5%3.0%5.2%13.7%
Net margin5.6%-17.4%17.0%3.3%5.1%11.5%
Return on equity3.1%-7.2%5.6%1.2%1.5%2.1%
Return on assets1.4%-3.5%2.8%0.6%1.2%1.8%
Free cash flow yield2.7%3.3%0.8%4.3%4.0%4.2%
Revenue growth38.2%25.6%-1.2%23.1%59.7%55.0%
Earnings growth-144.6%-229.0%408.1%-20.4%-29.3%59.9%
Current ratio1.40x2.40x2.89x2.19x2.17x5.24x
Debt to equity0.63x0.75x0.65x0.52x0.09x0.04x
Equity ratio45.4%48.6%49.5%52.3%74.8%86.5%
Interest coverage1.43x-2.35x2.78x0.79x4.58x34.73x
R&D as a share of sales24.4%32.6%51.6%30.9%30.2%34.2%
Buybacks as a share of market value-0.0%0.3%-0.9%0.6%0.6%-48.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue19.7%26.6%—
Operating income47.2%6.6%—
Net income43.0%10.5%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin94.4%93.3%93.7%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings233.5-66.2101.1——488.9—
Price to sales13.712.218.417.533.556.689.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.